Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.

Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV.

J Hepatol. 2007 Feb;46(2):213-21. Epub 2006 Nov 10.

PMID:
17156883
2.

Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?

Bansal S, Lindenfeld J, Schrier RW.

Circ Heart Fail. 2009 Jul;2(4):370-6. doi: 10.1161/CIRCHEARTFAILURE.108.821199. Review.

3.

Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.

Karwa R, Woodis CB.

Ann Pharmacother. 2009 Apr;43(4):692-9. doi: 10.1345/aph.1L373. Epub 2009 Mar 18. Review.

PMID:
19299324
4.

Pathogenesis and treatment of ascites in hepatic cirrhosis.

Gentilini P, La Villa G, Romanelli RG, Foschi M, Laffi G.

Cardiology. 1994;84 Suppl 2:68-79. Review.

PMID:
7954548
5.

Review: the controversy over the pathophysiology of ascites formation in cirrhosis.

Wong F, Girgrah N, Blendis L.

J Gastroenterol Hepatol. 1997 Jun;12(6):437-44. Review.

PMID:
9195401
6.

Mechanism of sodium retention and ascites formation in cirrhosis.

Arroyo V, Ginès P.

J Hepatol. 1993;17 Suppl 2:S24-8. Review.

PMID:
8491967
7.

Midodrine. A review of its therapeutic use in the management of orthostatic hypotension.

McClellan KJ, Wiseman LR, Wilde MI.

Drugs Aging. 1998 Jan;12(1):76-86. Review.

PMID:
9467688
8.

The renin-angiotensin-aldosterone system in human hepatic cirrhosis.

Bernardi M, Gasbarrini G.

Isr J Med Sci. 1986 Feb;22(2):70-7. Review.

PMID:
3512474
9.

Ascites in liver diseases.

Gentilini P, Laffi G.

Ann Ital Med Int. 1991 Jan-Mar;6(1 Pt 2):148-55. Review.

PMID:
1742150
10.

[Renal and extra-renal mechanisms of sodium and water retention in cirrhosis with ascites].

Peña JC.

Rev Invest Clin. 1995 Jan-Feb;47(1):63-79. Review. Spanish.

PMID:
7777718
11.

Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review.

Prakash S, Garg AX, Heidenheim AP, House AA.

Nephrol Dial Transplant. 2004 Oct;19(10):2553-8. Epub 2004 Jul 27. Review.

PMID:
15280522
12.

Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis.

Guo TT, Yang Y, Song Y, Ren Y, Liu ZX, Cheng G.

J Dig Dis. 2016 Jan;17(1):11-9. doi: 10.1111/1751-2980.12304. Review.

PMID:
26630543
13.

Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites.

Cárdenas A, Arroyo V.

Best Pract Res Clin Endocrinol Metab. 2003 Dec;17(4):607-22. Review.

PMID:
14687592
14.

Nitric oxide and renal function in cirrhotic patients with ascites: from physiopathology to practice.

Grangé JD, Amiot X.

Eur J Gastroenterol Hepatol. 2004 Jun;16(6):567-70. Review.

PMID:
15167158
15.

Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension.

Cruz DN.

Expert Opin Pharmacother. 2000 May;1(4):835-40. Review.

PMID:
11249519
16.

Pathogenesis of water and sodium retention in cirrhosis.

Martin PY, Schrier RW.

Kidney Int Suppl. 1997 Jun;59:S43-9. Review.

PMID:
9185104
17.

Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation.

Vaughan RB, Chin-Dusting JP.

Expert Opin Pharmacother. 2003 May;4(5):625-37. Review.

PMID:
12739989
18.

Pathogenesis of ascites and predictors of resistance to therapy.

De Franchis R, Salerno F.

J Gastroenterol Hepatol. 2002 Dec;17 Suppl 3:S242-7. Review.

PMID:
12472943
19.

Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review.

Rubinstein S, Haimov M, Ross MJ.

Ren Fail. 2008;30(8):808-12. doi: 10.1080/08860220802249025. Review.

PMID:
18791956
20.

Arterial hypertension and chronic liver disease.

Henriksen JH, Møller S.

Minerva Med. 2005 Aug;96(4):233-46. Review.

PMID:
16179891

Supplemental Content

Support Center